Project Details
| Status | Finished |
|---|---|
| Effective start/end date | 07/26/16 → 05/21/21 |
Funding
- Tocagen Incorporated: $75,324.60
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined with Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma (Toca 5)
- Davis, Raphael (PI)
- Chesler, David (CoPI)
- Gutman, Frederick (CoPI)
- Kowalska, Agnieszka (CoPI)
Project: Research